Combination therapy before surgery for early-stage EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether combining an EGFR-targeted pill with chemotherapy before surgery can shrink or control early-stage non-small cell lung cancer that has an EGFR mutation. It aims to improve outcomes for patients whose tumors can be removed surgically.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer with an EGFR mutation, confirmed by a biopsy.
- Your cancer is stage IIA to IIIB and can be removed with surgery.
- You have not had any prior treatment for this lung cancer, such as surgery, radiation, or chemotherapy.
- You are 18 years or older.
- You are generally healthy enough for surgery, with good organ function (liver, kidneys, blood counts).
- You have not had another cancer in the last 5 years (except for certain early-stage skin or cervical cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (firmonertinib and bevacizumab) given before surgery for people with early-stage, EGFR-mutated lung cancer. The goal is to shrink the tumor and improve the chances of successful surgery.
This trial tests a targeted therapy pill (firmonertinib) given before and after surgery for stage II–III lung adenocarcinoma that has an EGFR mutation. The goal is to see if this approach can shrink the tumor before surgery and reduce the chance of cancer coming back.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This trial tests a combination of two targeted medicines (befotertinib and bevacizumab) before surgery for people with EGFR-mutant non-small cell lung cancer that cannot be removed right away. The goal is to see if this treatment can shrink the tumor and improve surgery outcomes.
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
Hear when a new EGFR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.